Analytical Data
-
Gene name
ACVR2A
- Application
-
Alternative Names
ACVR2A；ACVR2；Activin receptor type-2A
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P27037
-
Expression Region
1-513aa
-
AA Sequence
MGAAAKLAFAVFLISCSSGAILGRSETQECLFFNANWEKDRTNQTGVEPC YGDKDKRRHCFATWKNISGSIEIVKQGCWLDDINCYDRTDCVEKKDSPEV YFCCCEGNMCNEKFSYFPEMEVTQPTSNPVTPKPPYYNILLYSLVPLMLI AGIVICAFWVYRHHKMAYPPVLVPTQDPGPPPPSPLLGLKPLQLLEVKAR GRFGCVWKAQLLNEYVAVKIFPIQDKQSWQNEYEVYSLPGMKHENILQFI GAEKRGTSVDVDLWLITAFHEKGSLSDFLKANVVSWNELCHIAETMARGL AYLHEDIPGLKDGHKPAISHRDIKSKNVLLKNNLTACIADFGLALKFEAG KSAGDTHGQVGTRRYMAPEVLEGAINFQRDAFLRIDMYAMGLVLWELASR CTAADGPVDEYMLPFEEEIGQHPSLEDMQEVVVHKKKRPVLRDYWQKHAG MAMLCETIEECWDHDAEARLSAGCVGERITQMQRLTNIITTEDIVTVVTM VTNVDFPPKESSL
-
Molecular Weight
83 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ACVR2A (Activin A receptor type 2A) is a key member of the transforming growth factor-beta (TGF-β) superfamily and plays a pivotal role in various biological processes, including cell growth, differentiation, and apoptosis. Research has shown that ACVR2A is implicated in the regulation of the muscle mass through its involvement in the activin signaling pathway, which can lead to muscle wasting in diseases such as cancer and aging. Dysregulation of ACVR2A has also been associated with various pathological conditions, including fibrotic diseases and certain types of cancer, underscoring its potential as a therapeutic target. Recombinant ACVR2A proteins have been developed to elucidate its biological functions and to explore their roles in therapeutics. These studies aim to provide insights into the molecular mechanisms by which ACVR2A contributes to disease progression and muscle homeostasis. Understanding the structure and function of ACVR2A through recombinant protein studies is critical for the development of novel treatments targeting the activin pathway, thereby offering hope for interventions in muscle degenerative diseases and other conditions linked to ACVR2A dysregulation.
